:
[...]
LEIDEN, The Netherlands & SEATTLE, Jul. 04, 2012 -- (BUSINESS WIRE) -- ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), will present the results of the company’s Fibrocaps Phase II (FC-002) trial, as well as the progress made by ProFibrix in its groundbreaking recombinant fibrinogen program at two international scientific conferences this week.
10th World Congress of the International Hepato-Pancreato-Biliary Association, July 1-5, Palais des Congres, Paris, France
Fibrocaps™, A Novel Fibrin Sealant, for Bleeding During Hepatic Resection: Results of a Phase 2, Randomized, Controlled Study
Presenter: Cornelis Verhoef MD, PhD, Division of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Center, the Netherlands
Date: July 5, 2012
Presentation Time: 8:45 – 10:30; Location: Room 253
XXIInd International Fibrinogen Workshop, the Biennial Meeting of the International Society on Fibrinogen Research (IFRS), 4-6 July, Thistle Hotel, Brighton, UK
Recombinant Human Fibrinogen: Production and Characterization
Presenter: Jos Grimbergen, Bsc . Director R&D, ProFibrix BV, Leiden, the Netherlands
Date: July 5, 2012
Presentation Time: 16:45 – 17:45; Location: Renaissance Ballroom
He Pas op ouwe Rover, niet pikken van andere draadjes.
Maar je dacht natuurlijk ik zal Beur even laten zien dat ik ook verstand van zaken heb.